PKCθ

PKCθ (protein kinase C theta, PRKCQ) is a member of the novel protein kinase C family that is selectively enriched in T lymphocytes and functions as a central mediator of antigen receptor signaling during adaptive immune responses^[1]. Upon productive T-cell receptor (TCR) engagement and CD28 costimulation, PKCθ is recruited to the immunological synapse, where it integrates signaling events required for full T-cell activation and interleukin-2 production^[1][2]. Mechanistically, PKCθ promotes activation of the transcription factors NF-κB, AP-1, and NFAT, thereby controlling T-cell activation, proliferation, survival, and differentiation programs^[1][3]. Phosphorylation-dependent regulation further governs PKCθ activity, membrane translocation, and downstream signaling efficiency during TCR-mediated responses^[3]. In disease-related contexts, PKCθ has been implicated in autoimmune and inflammatory processes through its regulation of effector T-cell function, T helper cell differentiation, and immune homeostasis^[3][4]. PKCθ also contributes to the balance between regulatory T cells and effector T cells, linking its activity to immune tolerance and pathogenic immune responses^[5]. Compared with related PKC isoforms, PKCθ displays a distinctive localization to the immunological synapse and a particularly prominent role in mature T-cell activation, making it a functionally specialized signaling kinase within the PKC family^[1][6]. For experimental applications, selective PKCθ inhibitors have been developed to suppress T-cell activation and cytokine production, supporting the use of PKCθ as a therapeutic and pharmacological target in studies of autoimmunity, transplantation, and T-cell-mediated inflammatory diseases^[4][7].